Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaokui Mo

Showing results (181-190 of 207) with videos related to

Pageof 21
Sort By:
Cancers|March 29, 2023
Hyperinsulinemic and Pro-Inflammatory Dietary Patterns and Metabolomic Profiles Are Associated with Increased Risk of Total and Site-Specific Cancers among Postmenopausal WomenQi Jin, Ni Shi, Dong Hoon Lee, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 11, 2024
Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneouslyWen Luo, Hai Hoang, Katherine E Miller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 27, 2023
Dose-Specific Intratumoral GM-CSF Modulates Breast Tumor Oxygenation and Antitumor ImmunityNicole E Mihalik, Kayla J Steinberger, Alyson M Stevens, et al.
Blood|December 8, 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathwayRosa Lapalombella, Leslie Andritsos, Qing Liu, et al.
Blood Advances|February 10, 2019
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinibEmily M McWilliams, Christopher R Lucas, Timothy Chen, et al.
Frontiers in Immunology|April 16, 2026
Fc gamma receptor binding modulates IgG clearance in cancer cachexiaBryan C Remaily, Kyeongmin Kim, Justin Thomas, et al.
Leukemia & Lymphoma|March 9, 2017
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomasDouglas W Sborov, Alessandro Canella, Erinn M Hade, et al.
Science Advances|July 20, 2022
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeuticsTimothy P Cripe, Brian Hutzen, Mark A Currier, et al.
International Journal of Radiation Oncology, Biology, Physics|August 13, 2023
Incident Atrial Fibrillation and Survival Outcomes in Esophageal Cancer following RadiotherapyEric D Miller, Trudy Wu, Grant McKinley, et al.
Pharmacological Research|December 25, 2023
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexiaTrang T Vu, Kyeongmin Kim, Millennium Manna, et al.
Pageof 21

Showing results (181-190 of 207) with videos related to

Sort By:
Pageof 21
Cancers|March 29, 2023
Hyperinsulinemic and Pro-Inflammatory Dietary Patterns and Metabolomic Profiles Are Associated with Increased Risk of Total and Site-Specific Cancers among Postmenopausal WomenQi Jin, Ni Shi, Dong Hoon Lee, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 11, 2024
Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneouslyWen Luo, Hai Hoang, Katherine E Miller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 27, 2023
Dose-Specific Intratumoral GM-CSF Modulates Breast Tumor Oxygenation and Antitumor ImmunityNicole E Mihalik, Kayla J Steinberger, Alyson M Stevens, et al.
Blood|December 8, 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathwayRosa Lapalombella, Leslie Andritsos, Qing Liu, et al.
Blood Advances|February 10, 2019
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinibEmily M McWilliams, Christopher R Lucas, Timothy Chen, et al.
Frontiers in Immunology|April 16, 2026
Fc gamma receptor binding modulates IgG clearance in cancer cachexiaBryan C Remaily, Kyeongmin Kim, Justin Thomas, et al.
Leukemia & Lymphoma|March 9, 2017
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomasDouglas W Sborov, Alessandro Canella, Erinn M Hade, et al.
Science Advances|July 20, 2022
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeuticsTimothy P Cripe, Brian Hutzen, Mark A Currier, et al.
International Journal of Radiation Oncology, Biology, Physics|August 13, 2023
Incident Atrial Fibrillation and Survival Outcomes in Esophageal Cancer following RadiotherapyEric D Miller, Trudy Wu, Grant McKinley, et al.
Pharmacological Research|December 25, 2023
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexiaTrang T Vu, Kyeongmin Kim, Millennium Manna, et al.
Pageof 21